Author, year | Study design | Enrolled Sample number (G1/G2) | Comparing | Anesthesia | Drug infiltration | Outcome measurement | Quality assessmenta | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
a | b | c | d | e | f | |||||||
Hirasawa, 2018 [14] | RCT | 45/45 | PAI, no PAI | GA | Rop 300 mg, Mor 8 mg, Methyl 40 mg, Keto 50 mg, Epi 0.3 mg | V | V | 5 | ||||
Ban WR,2017 [5] | RCT | 43/43 | PAI, no PAI | GA | Rop200mg, Keto 30 mg, Epi 0.3 mg | V | V | V | 5 | |||
Villatte, 2016 [6] | RCT | 75/75 | PAI, no PAI | GA | Rop 235 mg, Epi 0.5 mg | V | V | V | 5 | |||
Hofstad, 2015 [10] | RCT | 55/54 | PAI, no PAI | SA | Rop 300 mg, Epi 0.5 mg | V | V | 5 | ||||
den Hartog, 2015 [11] | RCT | 25/25 | PAI, no PAI | SA | Rop 200 mg, Epi 0.5 mg | V | V | 5 | ||||
Zoric, 2014 [12] | RCT | 29/29 | PAI, no PAI | GA | Rop 160 mg | V | V | V | 4 | |||
Dobie, 2012 [15] | RCT | 46/46 | PAI, no PAI | GA | Levo 160 mg | V | V | 5 | ||||
Murphy, 2012 [7] | RCT | 45/46 | PAI, no PAI | SA | Bup 150 mg | V | V | V | 5 | |||
Lunn, 2011 [13] | RCT | 60/60 | PAI, no PAI | SA | Rop 200 mg, Epi 1.5 mg | V | 5 | |||||
Liu, 2011 [8] | RCT | 40/40 | PAI, no PAI | SA | Bup 30 mg, Mor 5 mg, Bet 1 mg, Epi 0.5 mg | V | V | 5 | ||||
Busch, 2010 [9] | RCT | 32/31 | PAI, no PAI | SA or GA | Rop 40 mg, Keto 30 mg, Epi 0.5 mg | V | 4 |